BASEL, Switzerland, March 3, 2016 /PRNewswire/ -- What are the true benefits of innovation and can they be challenged? With innovation consistently highlighted as an important topic within the world of health care development, key stakeholders may be faced with the question as to whether or not innovation always leads to improvements. DIA is gearing up for the 28(th) Annual EuroMeeting [http://www.diaglobal.org/en/flagship/euromeeting-2016] and building a programme centered on the importance of proceeding down the correct paths and addressing the correct questions of innovation.
Key thought leaders across stakeholder groups come together at the EuroMeeting to exchange opinions, learn from one another and establish the best path forward in delivering positive outcomes for patients. With representation from 15+ regulatory authorities, including the European Medicines Agency (EMA), The European Commission and Japan Pharmaceuticals and Medical Devices Agency (PMDA), the forum provides a unique opportunity to hear directly from the regulators on the future of pharmaceutical and medical devices development.
This year's programme chairs set the stage for the DIA EuroMeeting forum collaboration across industry, regulatory agencies, academia and patients.
"We do not have many platforms available to bring people together from industry, academia, and regulatory agencies," said Karl Broich, President of BfArM and one of the EuroMeeting 2016 programme chairs. "The importance of DIA is that all these groups have an opportunity to exchange on these ideas in an informal way and to get new ideas, new proposals and new ways of how to do drug development."
According to Kemal Malik, Member of the Board of Management for Bayer and fellow EuroMeeting 2016 programme co-chair, "DIA provides a safe harbor forum where we, from the industry, can talk to people from regulatory authorities about issues that are common to us without the normal setting of a project. It's a very unique forum and one that should be cherished."
The conference will be held 6 - 8 April, 2016 in the Congress Center Hamburg, Germany and is open to registrants across all areas of pharmaceutical and medical device development.
For over 50 years, DIA (the Drug Information Association) has served as a neutral and transparent, global platform for more than 30,000 health care product development professionals, researchers, regulators, clinicians, academics and patient advocates to collaborate to improve health globally.
For more information, visit www.DIAglobal.org [http://www.diaglobal.org/].
CONTACT: DIA, EMEA@DIAglobal.org, +188.8.131.52.51
Web site: http://www.DIAglobal.org/